Jun 5 |
ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024
|
May 29 |
ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024
|
May 9 |
Acelyrin names Mina Kim as new Chief Executive Officer
|
May 9 |
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
|
May 9 |
ACELYRIN, INC. Announces Leadership Transition
|
Apr 29 |
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
|
Mar 28 |
Acelyrin GAAP EPS of -$5.43
|
Mar 28 |
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
|
Mar 27 |
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
|
Mar 20 |
Acelyrin gains after positive phase 1/2 data for thyroid eye disease drug
|